Summit Therapeutics and partners reported ivonescimab, a PD‑1xVEGF bispecific, cut progression or death by 40% versus a PD‑1 in a Chinese first‑line lung cancer trial; companies aim to start Phase 3 despite mixed global data. Summit indicated plans to submit to the FDA by year‑end for its PD‑1xVEGF bispecific while confronting earlier mixed Phase 3 readouts elsewhere. The ESMO presentations from Akeso and Summit strengthened the China cohort data and prompted the sponsor to push toward broader registrational testing. The program’s regulatory path will hinge on bridging global datasets and reconciling survival and safety signals across geographies and trial populations.